GSK launches puckish $15m "Sucks less" effort for Nicorette

Share this article:
GSK launches puckish $15m "Sucks less" effort for Nicorette
GSK launches puckish $15m "Sucks less" effort for Nicorette
GlaxoSmithKline Consumer Healthcare is taking an irreverent tone with its latest ads for Nicorette, featuring the tagline “Makes Quitting Suck Less.”

The $15 million campaign, by TBWA\Chiat\Day, is set to run through April and includes network TV and radio ads, along with an “Open letter to smokers” running in national mags and newspapers and on the brand's Facebook fan page.”

One broadcast spot depicts a driver stuck in traffic, his office carpool in the back seat. When he spies another driver smoking, a “Suckometer” perched in the passenger seat starts chirping, its needle moving toward the measure “Sucks more.” After he pops a tab of Nicorette, of course, the bleeping subsides and the needle goes back to “Sucks less.”

The campaign aims to connect with smokers by adopting the language they use to describe quitting, the company said.

“In order to truly connect with smokers, we realized that we needed to change how we speak to them about quitting,” said TBWA\Chiat\Day creative chief Mark Figliulo in a statement. “The campaign is designed to engage smokers in an honest way by reaching them with a message that shows the brand understands what they are going through, and that Nicorette is on their side.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...